“24 | IXEKIZUMAB WITH OR WITHOUT TIRZEPATIDE IN ADULTS WITH PSORIASIS AND OVERWEIGHT OR OBESITY: THE TOGETHER-PSO PHASE 3B RANDOMIZED CLINICAL TRIAL: E. Filippi1, M. Lebwohl2, A. Blauvelt3, C. Kartman4, C. Leatherwood4, K. Gordon5, N. Sattar6, L. Puig7, J. Merola8, K. Siu4, R. Wang4, L. Sun4, A. Leung9, N. Somani4, M. Rueda4, A. Cardoso4, M. Genovese4, A. Armstrong10, B. Strober11 | 1Eli Lilly Italy S.p.A, Sesto Fiorentino, Italy; 2Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 3Blauvelt Consulting, LLC, Annapolis, MD, USA; 4Eli Lilly and Company, Indianapolis, IN, USA; 5Department of Dermatology, Medical College of Wisconsin, Milwaukee, WI, USA; 6School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK; 7Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona School of Medicine, Barcelona, Spain; 8Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center and O’Donnell School of Public Health, Dallas, TX, USA; 9Syneos Health, Morrisville, NC, USA; 10Division of Dermatology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, CA, USA; 11Department of Dermatology, Yale University School of Medicine, New Haven, CT, Central Connecticut Dermatology Research, Cromwell, CT, USA” (2026) Dermatology Reports, 18(s1). doi:10.4081/dr.2026.11086.